» Articles » PMID: 37081888

Generation of a Symmetrical Trispecific NK Cell Engager Based on a Two-in-one Antibody

Overview
Journal Front Immunol
Date 2023 Apr 21
PMID 37081888
Authors
Affiliations
Soon will be listed here.
Abstract

To construct a trispecific IgG-like antibody at least three different binding moieties need to be combined, which results in a complex architecture and challenging production of these molecules. Here we report for the first time the construction of trispecific natural killer cell engagers based on a previously reported two-in-one antibody combined with a novel anti-CD16a common light chain module identified by yeast surface display (YSD) screening of chicken-derived immune libraries. The resulting antibodies simultaneously target epidermal growth factor receptor (EGFR), programmed death-ligand 1 (PD-L1) and CD16a with two Fab fragments, resulting in specific cellular binding properties on EGFR/PD-L1 double positive tumor cells and a potent ADCC effect. This study paves the way for further development of multispecific therapeutic antibodies derived from avian immunization with desired target combinations, valencies, molecular symmetries and architectures.

Citing Articles

Natural killer cell engagers for cancer immunotherapy.

Nikkhoi S, Li G, Hatefi A Front Oncol. 2025; 14:1483884.

PMID: 39911822 PMC: 11794116. DOI: 10.3389/fonc.2024.1483884.


Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.

Shin M, Oh E, Minn D Immune Netw. 2024; 24(5):e34.

PMID: 39513028 PMC: 11538608. DOI: 10.4110/in.2024.24.e34.


Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1.

Harwardt J, Geyer F, Schoenfeld K, Baumstark D, Molkenthin V, Kolmar H Antibodies (Basel). 2024; 13(2).

PMID: 38804304 PMC: 11130809. DOI: 10.3390/antib13020036.


The present and future of bispecific antibodies for cancer therapy.

Klein C, Brinkmann U, Reichert J, Kontermann R Nat Rev Drug Discov. 2024; 23(4):301-319.

PMID: 38448606 DOI: 10.1038/s41573-024-00896-6.

References
1.
Roth L, Grzeschik J, Hinz S, Becker S, Toleikis L, Busch M . Facile generation of antibody heavy and light chain diversities for yeast surface display by Golden Gate Cloning. Biol Chem. 2018; 400(3):383-393. DOI: 10.1515/hsz-2018-0347. View

2.
Lacouture M . Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6(10):803-12. DOI: 10.1038/nrc1970. View

3.
Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

4.
Segaert S, Van Cutsem E . Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16(9):1425-33. DOI: 10.1093/annonc/mdi279. View

5.
Beck A, Wurch T, Bailly C, Corvaia N . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345-52. DOI: 10.1038/nri2747. View